Free Trial
→ Your book attached (From Profits Run) (Ad)tc pixel
NASDAQ:IMUX

Immunic Q3 2026 Earnings Date & Estimates

Immunic logo
$6.97 -0.13 (-1.83%)
Closing price 10/16/2026 04:00 PM Eastern
Extended Trading
$7.02 +0.04 (+0.65%)
As of 10/16/2026 07:30 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Immunic is estimated to report Q3 2026 earnings on Thursday, November 12, 2026. The conference call is scheduled for 9:30 AM ET.

Research:ProfileEarnings HistoryForecast

Upcoming Earnings Announcement

Quarter
Q3 2026
Announcement Date
Conference Call
9:30 AM ET
Google Calendar (opens in a new tab)Outlook (opens in a new tab)Yahoo Calendar (opens in a new tab)

What Analysts Expect from Immunic in Q3 2026

Immunic is expected to post earnings of -$0.9415 per share. In the same quarter a year earlier Immunic reported -$1.30 per share. Immunic last reported on August 11, 2026, posting -$0.80 per share and beating the -$1.16 consensus estimate. Immunic has beaten the consensus EPS estimate in 3 of its last 8 quarters.

Consensus Estimates

Consensus EPS
-$0.9415
Prior-Year EPS
-$1.30

Recent Track Record

Last Reported
Q2 2026
Last Quarter EPS
-$0.80 (Beat by +$0.36)
EPS Beat Rate
3 of last 8 quarters

Prepare for the Q3 2026 Call

Immunic Q3 2026 Earnings FAQ

Immunic (NASDAQ:IMUX) is estimated to report Q3 2026 earnings on Thursday, November 12, 2026. This date is estimated from past reporting schedules and may change once the company confirms it.

Immunic's Q3 2026 earnings conference call is scheduled for Thursday, November 12, 2026 at 9:30 AM ET. MarketBeat streams the conference call audio and posts the transcript as soon as possible on the earnings announcement date.

Analysts expect Immunic to post earnings of -$0.9415 per share for Q3 2026.

Immunic Earnings Headlines

Stifel Nicolaus Remains a Buy on Immunic (IMUX)
October 10, 2026  |  theglobeandmail.comhttps://www.theglobeandmail.com/investing/markets/stocks/IMUX/pressreleases/5354282/stifel-nicolaus-remains-a-buy-on-immunic-imux/
Immunic (NASDAQ:IMUX) Stock Bumped Down to "Sell" by Wall Street Zen
October 10, 2026  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=31104280
The $15 Gold Fund That Pays Up to $1,152/Month
Gold is hitting record highs, but most investors are leaving income on the table. A $15 fund is quietly paying out up to $1,152 a month to regular investors - no mining stocks, no options, no physical metal required. Chief Income Strategist Tim Plaehn calls it a breakthrough strategy that transforms gold's rally into reliable monthly payouts. The next distribution is just days away.tc pixel
October 17 at 1:00 AM  |  Investors Alley (Ad)
Immunic to Present New Clinical, Biomarker and Preclinical Data on Vidofludimus Calcium at MSToronto2026 the 10th Joint ACTRIMS-ECTRIMS Meeting
October 8, 2026  |  marketscreener.comM
Immunic to present four vidofludimus calcium abstracts at MSToronto2026
October 7, 2026  |  proactiveinvestors.comhttps://www.proactiveinvestors.com/companies/news/1099751?snapi
Immunic to Present New Clinical, Biomarker and Preclinical Data on Vidofludimus Calcium at MSToronto2026 - the 10th Joint ACTRIMS-ECTRIMS Meeting
October 7, 2026  |  prnewswire.comhttps://www.prnewswire.com/news-releases/immunic-to-present-new-clinical-biomarker-and-preclinical-data-on-vidofludimus-calcium-at-mstoronto2026--the-10th-joint-actrims-ectrims-meeting-302901094.html
See More Immunic Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Immunic? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Immunic and other key companies, straight to your email.

About Immunic

Immunic (NASDAQ:IMUX) is a clinical-stage biotechnology company developing orally administered therapies for chronic inflammatory and autoimmune diseases. The company focuses on selectively modulating the immune system while seeking to avoid broad immunosuppression, with an emphasis on conditions affecting the central nervous system and gastrointestinal tract.

Immunic’s lead investigational product is vidofludimus calcium, formerly known as IMU-838. The oral, selective dihydroorotate dehydrogenase inhibitor is being studied in clinical trials for multiple sclerosis, including relapsing and progressive forms of the disease. Immunic is also advancing earlier-stage programs such as IMU-856, which targets Sirtuin 6 and is being evaluated for intestinal disorders, and IMU-381, an investigational molecule intended for immune-mediated diseases.

Immunic was established in 2016 and became a publicly traded company in 2019 through a merger with Vital Therapies, subsequently adopting the Immunic name. The company maintains operations in the United States and Germany, including corporate activities in Waltham, Massachusetts, and research and development operations in Germany. Its programs are investigational and remain subject to clinical testing and regulatory review.

View Immunic Profile
Earnings Tools